MedTrace Logo

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

NCT00701662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-08-01

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess efficacy, safety, and convenience of purified human antibodies administered under the skin in the treatment of MMN patients.

Conditions

  • Multifocal Motor Neuropathy (MMN)

Interventions

BIOLOGICAL

Vivaglobin

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Matthias Sturzenegger, MD · Inselspital, University Hospital of Bern

  • Bernd Kieseier, MD · Neurologische Klinik, Heinrich-Heine-University, Düsseldorf

  • Giancarlo Comi, MD · San Raffaele Hospital

  • Siraj Misbah, MD · Dept. Clinical Immunology, Oxford Radcliffe Hospitals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Italy
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701662 on ClinicalTrials.gov